| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
|
Bisogno, Gianni
|
|
2018
|
19 |
8 |
p. 1061-1071
|
artikel
|
| 2 |
Adrenocortical carcinoma misdiagnosed as hepatocellular carcinoma
|
Chen, Hao-Wei
|
|
2018
|
19 |
8 |
p. e429
|
artikel
|
| 3 |
A roadmap for restoring trust in Big Data
|
Lawler, Mark
|
|
2018
|
19 |
8 |
p. 1014-1015
|
artikel
|
| 4 |
A virtual musician quartet with vestibular schwannoma
|
Tuleasca, Constantin
|
|
2018
|
19 |
8 |
p. 1025
|
artikel
|
| 5 |
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
|
Rutkowski, Stefan
|
|
2018
|
19 |
8 |
p. e419-e428
|
artikel
|
| 6 |
Breast cancer in a Renaissance Book of the Dead
|
Nicholls, Emma
|
|
2018
|
19 |
8 |
p. 1023-1024
|
artikel
|
| 7 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now
|
Sclafani, Francesco
|
|
2018
|
19 |
8 |
p. 1009-1011
|
artikel
|
| 8 |
Carcinogenicity of isobutyl nitrite, β-picoline, and some acrylates
|
Kromhout, Hans
|
|
2018
|
19 |
8 |
p. 1020-1022
|
artikel
|
| 9 |
Cervical HPV testing versus cytology
|
Burki, Talha Khan
|
|
2018
|
19 |
8 |
p. e390
|
artikel
|
| 10 |
Clinical and genomic features of a subtype of prostate cancer
|
Venkatesan, Priya
|
|
2018
|
19 |
8 |
p. e394
|
artikel
|
| 11 |
Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review
|
van der Meulen, Matthijs
|
|
2018
|
19 |
8 |
p. e407-e418
|
artikel
|
| 12 |
Convection-enhanced delivery: chemosurgery in diffuse intrinsic pontine glioma
|
van Vuurden, Dannis G
|
|
2018
|
19 |
8 |
p. 1001-1003
|
artikel
|
| 13 |
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
|
Souweidane, Mark M
|
|
2018
|
19 |
8 |
p. 1040-1050
|
artikel
|
| 14 |
Correction to Lancet Oncol 2018; 19: 1019–20
|
|
|
2018
|
19 |
8 |
p. e382
|
artikel
|
| 15 |
Correction to Lancet Oncol 2018; 19: 953–64
|
|
|
2018
|
19 |
8 |
p. e382
|
artikel
|
| 16 |
Correction to Lancet Oncol 2018; 19: 1040–50
|
|
|
2018
|
19 |
8 |
p. e382
|
artikel
|
| 17 |
Correction to Lancet Oncol 2018; 19: e386
|
|
|
2018
|
19 |
8 |
p. e382
|
artikel
|
| 18 |
CXCR4-targeted therapy in breast cancer
|
Derlin, Thorsten
|
|
2018
|
19 |
8 |
p. e370
|
artikel
|
| 19 |
Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres
|
Sirohi, Bhawna
|
|
2018
|
19 |
8 |
p. e395-e406
|
artikel
|
| 20 |
Digital oncology apps: revolution or evolution?
|
The Lancet Oncology,
|
|
2018
|
19 |
8 |
p. 999
|
artikel
|
| 21 |
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
|
Kim, Stefano
|
|
2018
|
19 |
8 |
p. 1094-1106
|
artikel
|
| 22 |
Does aspirin have a role in management of ovarian cancer?
|
Webb, Penelope M
|
|
2018
|
19 |
8 |
p. 1011-1012
|
artikel
|
| 23 |
Enzalutamide and metastasis risk in prostate cancer
|
Gourd, Elizabeth
|
|
2018
|
19 |
8 |
p. e387
|
artikel
|
| 24 |
Fruquintinib for previously treated metastatic colorectal cancer
|
Burki, Talha Khan
|
|
2018
|
19 |
8 |
p. e388
|
artikel
|
| 25 |
Gastrointestinal cancers in patients with cystic fibrosis
|
Maisonneuve, Patrick
|
|
2018
|
19 |
8 |
p. e368
|
artikel
|
| 26 |
Gastrointestinal cancers in patients with cystic fibrosis – Authors' reply
|
Yamada, Akihiro
|
|
2018
|
19 |
8 |
p. e369
|
artikel
|
| 27 |
Growing pains for US proton therapy
|
Furlow, Bryant
|
|
2018
|
19 |
8 |
p. 1019-1020
|
artikel
|
| 28 |
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
|
Friedlander, Michael
|
|
2018
|
19 |
8 |
p. 1126-1134
|
artikel
|
| 29 |
Knowledge-based drug discovery intensifies private appropriation of publicly financed research
|
Link, Wolfgang
|
|
2018
|
19 |
8 |
p. 1017-1018
|
artikel
|
| 30 |
Lung cancer in the UK: addressing geographical inequality and late diagnosis
|
Hiom, Sara C
|
|
2018
|
19 |
8 |
p. 1015-1017
|
artikel
|
| 31 |
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
|
Rahbar, Kambiz
|
|
2018
|
19 |
8 |
p. e371
|
artikel
|
| 32 |
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
|
Derlin, Thorsten
|
|
2018
|
19 |
8 |
p. e372
|
artikel
|
| 33 |
[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply
|
Hofman, Michael S
|
|
2018
|
19 |
8 |
p. e373
|
artikel
|
| 34 |
Mammography deficiencies: the result of poor positioning
|
Gourd, Elizabeth
|
|
2018
|
19 |
8 |
p. e385
|
artikel
|
| 35 |
Much ado about robotic versus open radical prostatectomy
|
Sharma, Vidit
|
|
2018
|
19 |
8 |
p. 1003-1004
|
artikel
|
| 36 |
New genetic discoveries in prostate cancer
|
Gourd, Elizabeth
|
|
2018
|
19 |
8 |
p. e383
|
artikel
|
| 37 |
No benefit of guideline-based therapy for rectal cancer
|
Das, Manjulika
|
|
2018
|
19 |
8 |
p. e392
|
artikel
|
| 38 |
Non-invasive image-guided targeted drug delivery
|
Haemmerich, Dieter
|
|
2018
|
19 |
8 |
p. 1000-1001
|
artikel
|
| 39 |
Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation
|
Kruser, Tim J
|
|
2018
|
19 |
8 |
p. e366
|
artikel
|
| 40 |
Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation – Authors' reply
|
Long, Georgina V
|
|
2018
|
19 |
8 |
p. e367
|
artikel
|
| 41 |
Optimising surveillance for relapse of Wilms' tumour
|
Lovvorn III, Harold N
|
|
2018
|
19 |
8 |
p. 1006-1007
|
artikel
|
| 42 |
PARP inhibitors and quality of life in ovarian cancer
|
Aoki, Daisuke
|
|
2018
|
19 |
8 |
p. 1012-1014
|
artikel
|
| 43 |
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
|
Adkins, Douglas
|
|
2018
|
19 |
8 |
p. 1082-1093
|
artikel
|
| 44 |
Pelvic IMRT reduces toxicity vs standard radiotherapy
|
Gourd, Elizabeth
|
|
2018
|
19 |
8 |
p. e393
|
artikel
|
| 45 |
Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study
|
Merritt, Melissa A
|
|
2018
|
19 |
8 |
p. 1107-1116
|
artikel
|
| 46 |
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
|
Oza, Amit M
|
|
2018
|
19 |
8 |
p. 1117-1125
|
artikel
|
| 47 |
Refametinib in RAS-mutated hepatocellular cancer
|
Das, Manjulika
|
|
2018
|
19 |
8 |
p. e389
|
artikel
|
| 48 |
Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group–International Society of Paediatric Oncology Wilms' tumour protocol database
|
Brok, Jesper
|
|
2018
|
19 |
8 |
p. 1072-1081
|
artikel
|
| 49 |
Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study
|
Coughlin, Geoffrey D
|
|
2018
|
19 |
8 |
p. 1051-1060
|
artikel
|
| 50 |
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial
|
Lyon, Paul C
|
|
2018
|
19 |
8 |
p. 1027-1039
|
artikel
|
| 51 |
Sex as a predictor of response to cancer immunotherapy
|
Kwon, Hyunwoo
|
|
2018
|
19 |
8 |
p. e379
|
artikel
|
| 52 |
Sex as a predictor of response to cancer immunotherapy
|
Liang, Fei
|
|
2018
|
19 |
8 |
p. e378
|
artikel
|
| 53 |
Sex as a predictor of response to cancer immunotherapy
|
McQuade, Jennifer L
|
|
2018
|
19 |
8 |
p. e376
|
artikel
|
| 54 |
Sex as a predictor of response to cancer immunotherapy
|
Zhang, Tao
|
|
2018
|
19 |
8 |
p. e374
|
artikel
|
| 55 |
Sex as a predictor of response to cancer immunotherapy
|
Carrera, Cristina
|
|
2018
|
19 |
8 |
p. e375
|
artikel
|
| 56 |
Sex as a predictor of response to cancer immunotherapy
|
Claggett, Brian
|
|
2018
|
19 |
8 |
p. e377
|
artikel
|
| 57 |
Sex as a predictor of response to cancer immunotherapy – Authors' reply
|
Conforti, Fabio
|
|
2018
|
19 |
8 |
p. e380-e381
|
artikel
|
| 58 |
SRS is non-inferior to WBRT for brain metastases
|
Venkatesan, Priya
|
|
2018
|
19 |
8 |
p. e386
|
artikel
|
| 59 |
Systemic therapy after IFRT for follicular lymphoma
|
Venkatesan, Priya
|
|
2018
|
19 |
8 |
p. e391
|
artikel
|
| 60 |
Targeting VEGF and EGFR: a combination worth re-exploring?
|
Tchekmedyian, Vatche
|
|
2018
|
19 |
8 |
p. 1007-1009
|
artikel
|
| 61 |
The power of blood and bone
|
Stirrups, Robert
|
|
2018
|
19 |
8 |
p. 1026
|
artikel
|
| 62 |
Urologists reduce overtreatment in prostate cancer
|
Das, Manjulika
|
|
2018
|
19 |
8 |
p. e384
|
artikel
|
| 63 |
When treatment does not work: failure to understand failure
|
Wexler, Leonard H
|
|
2018
|
19 |
8 |
p. 1004-1006
|
artikel
|
Tijdschrift beschrijving